HKDC1 C-terminal based peptides inhibit extranodal natural killer/T-cell lymphoma by modulation of mitochondrial

Qi Chen1, Jia Feng1, Jinhu Wu2

  • 1Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, 518036, PR China.

Leukemia
|March 24, 2020
PubMed

Insights

A novel peptide targeting hexokinase domain component 1 (HKDC1) effectively inhibits extranodal nasal-type natural killer/T-cell lymphoma (ENKTL) growth. This peptide suppresses Epstein-Barr virus (EBV) replication and P-glycoprotein expression by disrupting mitochondrial function.

Area of Science:

  • Oncology
  • Virology
  • Biochemistry

Background:

  • Extranodal nasal-type natural killer/T-cell lymphoma (ENKTL) is an aggressive, relapsing lymphoma associated with Epstein-Barr virus (EBV).
  • Advanced ENKTL exhibits chemoresistance and a poor prognosis, necessitating novel therapeutic strategies.
  • Hexokinase domain component 1 (HKDC1) is implicated in antimetabolic pathways, EBV replication, and P-glycoprotein (P-gp) expression in ENKTL.

Purpose of the Study:

  • To develop a novel HKDC1-based antitumor target for ENKTL.
  • To investigate the role of HKDC1 in ENKTL pathogenesis, including its involvement in EBV replication and P-gp expression.
  • To evaluate the therapeutic potential of a targeted peptide derived from HKDC1.

Main Methods:

  • HKDC1 expression levels were analyzed in ENKTL cells.
  • HKDC1 knockdown was performed to assess its impact on tumor growth.
  • A peptide (Tf-D-HKC8) targeting the C-terminal of HKDC1 was designed and synthesized.
  • The peptide's mechanism of action, including effects on mitochondrial function, EBV replication, and P-gp expression, was investigated.
  • In vivo efficacy was evaluated using ENKTL xenograft mouse models.

Main Results:

  • HKDC1 was significantly upregulated in ENKTL cells, and its knockdown suppressed tumor growth.
  • The Tf-D-HKC8 peptide inhibited the association of HKDC1 with VDAC1, leading to mitochondrial dysfunction and reactive oxygen species (ROS) overgeneration.
  • The peptide effectively suppressed EBV replication and P-gp expression in ENKTL cells.
  • Local injection of Tf-D-HKC8 peptide significantly inhibited tumor growth and EBV replication in vivo.

Conclusions:

  • HKDC1 is a critical target for ENKTL therapy.
  • The C-terminal peptide Tf-D-HKC8 demonstrates potent antitumor activity against ENKTL by modulating mitochondrial function and suppressing EBV.
  • HKDC1-based peptides represent a promising therapeutic approach for EBV-positive ENKTL.

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K
Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
8.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K